USA: Post-Doc Position Human Monoclonal Antibody Development for Liver Cancer Therapy at National Institutes of Health (NIH)

Font size: Decrease font Enlarge font

 Description: postdoctoral position is available in the Laboratory of Molecular Biology, National Cancer Institute at the NIH campus in Bethesda. We are seeking a highly motivated postdoctoral fellow to join our antibody development group. In this position, you will work on antibody library construction and the development of human monoclonal antibodies for cancer therapy with a focus on hepatocellular carcinoma.

Eligiility: The applicant should have a Ph.D. or Ph.D./M.D. degree (awarded within the past four years) in molecular biology, microbiology, immunology, cell biology, biochemistry or a related discipline. Research experience in animal testing, protein purification, signaling pathways, immunohistochemistry, cancer stem cells, phage display, yeast display, and/or mammalian display will be a plus.

Research in our lab aims to understand the molecular mechanisms underlying cancer pathogenesis and to develop novel antibody-based cancer therapies. In particular, we are interested in generating new human monoclonal antibodies to treat liver cancer as well as other cancers. We have used in vitro tumor spheroids in the field of antibody therapy and developed mammalian cell display for the identification of therapeutic antibodies. Additional information about our research activities can be found on our web page:http://ccr.cancer.gov/staff/staff.asp?profileid=7668.

To Apply:

Interested applicants should send a cover letter describing your research experience and interests, CV including bibliography, and contact information for three references to:

Mitchell Ho, Ph.D.
Chief, Antibody Therapy Section
Laboratory of Molecular Biology, NCI
Building 37, Room 5002C
37 Convent Drive
Bethesda, MD 20892
Phone: (301) 451-8727
Fax : (301) 402-1344
E-mail: homi(at)mail.nih.gov

Be Sociable, Share!

No Comments

Post your comment comment

You must be logged in to post a comment.